Insulet and Tandem Q3 ’18 Earnings Updates

Insulet and Tandem hosted their Q3 ’18 earnings calls and provided updates to their respective diabetes device portfolios. Of note, Insulet announced that the Omnipod Horizon automated insulin delivery (AID) system will be controlled directly by the user’s smartphone. If approved, Horizon is anticipated to be the first smartphone-controlled insulin pump. Recall, Tandem also plans to utilize smartphone control for its t:sport pump. Below are highlights from the respective earnings calls.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.